Stroke

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

Data from more than 800 patients with 120 days of continuous heart monitoring data and ischemic stroke provide insight into the timing of arrhythmic episodes and how it can help predict the risk of stroke in patients with CIEDs and atrial fibrillation.

Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.

Data from a recent analysis suggests patients with diabetes with the lowest levels of insulin resistance had a 40% lower risk of stroke when compared to those with the highest levels.

Abbott announced on September 29 the FDA had granted approval to the Amplatzer Talisman PFO Occluder for use in patients with a PFO at risk of recurrent stroke. This approval was accompanied by the clearance of the Amplatzer Talisman Delivery Sheath.

After presenting at TMIOA's 5th Heart in Diabetes meeting, Silvio Inzucchi, MD, reviews current knowledge related to the effects of diabetes medications on stroke risk.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

The Amulet IDE Trial is the first trial to offer a head-to-head comparison of the Amplatzer Amulet occluder from Abbot against the Watchman device from Boston Scientific for left atrial appendage occlusion.

Data from the Salt Substitute and Stroke Study suggest switching from regular salt to a salt substitute could reduce the risk of stroke by 14% and investigators believe these results can be applied to patient populations across the world.

Despite increasing detection of atrial fibrillation and rates of anticoagulation, continuous electrocardiographic monitoring with an implantable loop recorder did not significantly reduce risk of stroke in the LOOP study.

An ESC Congress 2021 analysis suggests icosapent ethyl was associated with a 35% reduction in total primary end point events among patients with a history of myocardial infarction prior to enrollment in the REDUCE-IT trial.

The vagus nerve stimulation system is the first of its kind stroke rehabilitation system, after supporting data from the VNS-REHAB trial suggested its efficacy in improving FMA-UE scores.

All NOACs had a lower risk of stroke or SE compared to warfarin, including apixaban, dabigatran, and rivaroxaban.

A meta-analysis with data from nearly 60k patients suggests presence of metabolic syndrome was associated with a 46% increase in risk of a second stroke and a 27% increase in risk of mortality among stroke survivors when compared to their counterparts without metabolic syndrome.

A 412-patient trial comparing 3 dosing regimens of abelacimab versus enoxaparin, results indicate all 3 regimens of abelacimab demonstrated noninferiority against enoxaparin and 2 of the 3 demonstrated superiority against the current standard of care.

The American Heart Association and American Stroke Association recognize the important role of primary care in patient management following a stroke.

Simultaneously published in JAMA, the PER DIEM and STROKE-AF trials demonstrate the ability of Medtronic's insertable cardiac monitor, Reveal LlNQ, to improve detection of atrial fibrillation in patients with a history of stroke.

The American Heart Association and American Stroke Association have released an updated version of their guidelines for prevention of secondary stroke in patients with stroke or TIA, which had not been updated since 2014.

Results of the LAAOS III trial provide evidence suggesting left atrial appendage occlusion could reduce risk of ischemic events by nearly a third and also reduce risk of stroke by more than 40% in patients with atrial fibrillation.

The first episode of the Heart Trials podcast series focuses on new ACC 2021 research into aspirin dosages for reduced cardiovascular event risk.

An analysis of nearly 2 million patients suggests an increased BMI around the age of 18 was linked to a graded increase in the risk of ischemic stroke in midlife, regardless of diabetes status.

The American Heart Association and American Stroke Association have released a special report related to the treatment of blood clots or low platelet counts related to the COVID-19 vaccine, which has garnered mass amounts of attention despite being a rare complication.

Dr. Gregory Weiss, a cardiovascular anesthesiologist, breaks down and provides real-world perspective on the application of a recent scientific statement from the AHA and ASA on perioperative management to lower stroke risk in patients undergoing noncardiac and nonneurological procedures.

An analysis of claims data by investigators at University of Pennsylvania indicates DOACs were associated with a 36% lower risk of stroke or systemic embolism and was also associated with a reduction in risk of major bleeding.

Check out this interview with Louise McCullough, MD, PhD, Program Chair of ISC 21, where she offers perspective on mobile stroke units and what barriers prevent further implementation of the specialized ambulatory units.